FOLOTYN

This brand name is authorized in United States. It is also authorized in Australia, Canada, Singapore.

Active ingredients

The drug FOLOTYN contains one active pharmaceutical ingredient (API):

1	Pralatrexate UNII A8Q8I19Q20 - PRALATREXATE
	Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer. Pralatrexate is used for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
	Read more about Pralatrexate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FOLOTYN Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BA05		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11271F, 11272G, 11278N, 11293J
CA	Health Products and Food Branch	02481820
SG	Health Sciences Authority	14544P
US	FDA, National Drug Code	48818-001, 72893-003, 72893-005